Company Profile
Cidara Therapeutics Stock Price, News & Analysis
- Ticker:
- CDTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for CDTX.
Company overview
Business overview
Cidara Therapeutics is an anti-infective and immunotherapy company focused on drug-conjugate and engineered-therapy approaches. Its platform is aimed at serious infectious disease and immune-mediated conditions.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cidara sits in specialty biotechnology.
Business Model Characteristics
The business depends on clinical data, platform validation, and the ability to create a differentiated anti-infective franchise.
Position Within the Biotechnology Landscape
Cidara is a catalyst-sensitive anti-infective name with meaningful dependence on program progress.
Future catalysts
Cidara’s catalysts are CD388 and the broader antiviral/immunology platform, where the market will watch for development steps that show the lead asset can keep advancing. The company still needs clinical validation to keep the thesis strong.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Cidara Therapeutics do?
Cidara Therapeutics is an anti-infective and immunotherapy company focused on drug-conjugate and engineered-therapy approaches. Its platform is aimed at serious infectious disease and immune-mediated conditions.
On which exchange is CDTX stock listed?
Cidara Therapeutics (CDTX) is associated with NASDAQ, United States, Biopharma.
What is Cidara?
Cidara’s catalysts are CD388 and the broader antiviral/immunology platform, where the market will watch for development steps that show the lead asset can keep advancing.
Which conditions is Cidara Therapeutics targeting with Cidara?
Cidara Therapeutics is associated with immunology based on its company overview and current catalyst commentary.
How does Cidara Therapeutics describe recent progress with Cidara?
Cidara’s catalysts are CD388 and the broader antiviral/immunology platform, where the market will watch for development steps that show the lead asset can keep advancing.
What is Therapeutics?
Cidara Therapeutics is an anti-infective and immunotherapy company focused on drug-conjugate and engineered-therapy approaches.
What should investors watch for with Therapeutics?
Cidara’s catalysts are CD388 and the broader antiviral/immunology platform, where the market will watch for development steps that show the lead asset can keep advancing. The company still needs clinical validation to keep the thesis strong.
What is CD388?
Cidara’s catalysts are CD388 and the broader antiviral/immunology platform, where the market will watch for development steps that show the lead asset can keep advancing.